Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corp (NQ: GERN )

4.070 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Geron Corp

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Friday. Shares of Argan, Inc. (NYSE: AGX) rose sharply during Friday’s session as the company reported better-than-expected... 
Via Benzinga
Topics Stocks
Exposures US Equities
Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is 'Too Speculative For Me'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said "no" to MarineMax Inc (NYSE: HZO). 
Via Benzinga
The Latest Analyst Ratings For Geron
Via Benzinga
Geron Corp. (NASDAQ: GERN) Near Top of Volume Charts in Friday Trading
Via Investor Brand Network
Geron to Participate at Upcoming Investor Conferences in April
From Geron Corporation
Via Business Wire
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
Exposures Product Safety
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Geron Corporation
Via Business Wire
Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is in buyout talks with Advent International. Nuvei shares jumped 14.1% to... 
Via Benzinga
Logitech, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining by around 100 points on Monday. Shares of Logitech International S.A. (NASDAQ: LOGI) fell in today’s pre-market... 
Via Benzinga
Inflation Squeezes Stocks, Bitcoin Slips To $68,000, While Commodities On Track For Best Week In Months: What's Driving Markets Friday?
Wall Street continues to maintain a risk-off sentiment in Friday’s session, echoing the pessimism triggered by Thursday’s unexpectedly high producer inflation figures. 
Via Benzinga
Topics Economy
Exposures Interest Rates
What's Going On With Cancer Focused-Geron Stock On Friday?
Geron sees lower share price with high volume. FDA committee votes favorably on imetelstat for transfusion-dependent anemia in adult MDS patients. June 16, 2024, set as FDA target action date.... 
Via Benzinga
Exposures Product Safety
Why Is Geron (GERN) Stock Up 94% Today?
Geron stock is on the rise Friday with heavy trading of GERN shares after the company's blood disorder drug got new backing. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Geron Stock Is Soaring After Hours: What's Going On?
Geron shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food and Drug Administration's (FDA) Oncologic drugs advisory committee (ODAC) voted in favor of the... 
Via Benzinga
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
From Geron Corporation
Via Business Wire
Why Geron Stock Is Falling Today
Geron shares are trading lower Tuesday after a Reuters report stated FDA staff reviewers raised multiple safety concerns over Geron's anemia drug, imetelstat. According to the report, FDA staff said... 
Via Benzinga
Exposures Product Safety
FDA Casts Doubts On Geron's Blood Cancer Drug, But Analyst Sees High Probability For Imetelstat's Potential Approval For MDS Anemia Treatment
The FDA's review of Geron Corporation's imetelstat application for anemia in lower-risk MDS patients. Expert analysis suggests a favorable AdComm vote and potential full FDA approval by the June 16,... 
Via Benzinga
Exposures Product Safety
Geron (GERN) Q4 2023 Earnings Call Transcript
GERN earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. 
Via Benzinga
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Participate in the B. Riley Securities Virtual Oncology Conference
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
From Geron Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.